IL1B and cryopyrin-associated periodic syndrome: Indeed studies with anakinra, a non-glycosylated form of the endogenous antagonist of the IL-1 receptor, IL-1Ra, and rilonacept, which binds to IL-1β with high affinity and thus blocks the binding of IL-1β to its receptor, have demonstrated promising therapeutic activity in patients with CAPS [10-12].